Skip to main content
Erschienen in: Supportive Care in Cancer 8/2014

01.08.2014 | Original Article

Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients

verfasst von: Karin Garming Legert, Mats Remberger, Olle Ringdén, Anders Heimdahl, Göran Dahllöf

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Oral mucositis (OM) is a side effect of intensive chemotherapy and radiation and has been reported to affect 75–100 % of hematopoietic stem cell transplantation (HSCT) recipients. The purpose of this study was to compare the incidence of OM in patients conditioned with myeloablative conditioning (MAC) to reduced-intensity conditioning (RIC) and to determine the effect of a new oral care protocol.

Methods

The study involved 171 HSCT recipients, with hematological malignancies transplanted between 2007 and 2011. Median age of the patients was 50 years (range 12–71). Ninety-nine (58 %) received RIC and 72 received MAC. Clinical features of OM were recorded from day −3 before to day +25 after HSCT using the World Health Organization (WHO) scoring system and the oral mucositis assessment score (OMAS).

Results

Overall, 87 % of the patients developed OM of any severity, which peaked on days 10–11. The mean WHO score was 1.7. In multivariate analysis, the severity of OM was associated with MAC (relative hazard (RH) 1.57, 95 % confidence interval (CI) 1.37–1.80, p < 0.001), all donor-recipient gender combinations except female-to-male (RH = 1.26, 95 % CI 1.10–1.4, p = 0.001), and early year of HSCT (RH = 0.84, 95%CI 0.7–0.96, p = 0.013). There was a correlation between long hospitalization and OM (day 15, r = 0.31, p < 0.001). There was a good correlation between the WHO and OMAS scoring systems for OM (r = 0.74, p < 0.001).

Conclusions

Oral mucositis was reduced in patients treated with RIC and in patients treated during recent years, when oral care was intensified. Increased scores of OM prolonged hospitalization.
Literatur
1.
Zurück zum Zitat Heimdahl A, Johnson G, Danielsson K et al (1985) Oral condition of patients with leukemia and severe aplastic anemia. Oral Surg Oral Med Oral Pathol 60:498–504PubMedCrossRef Heimdahl A, Johnson G, Danielsson K et al (1985) Oral condition of patients with leukemia and severe aplastic anemia. Oral Surg Oral Med Oral Pathol 60:498–504PubMedCrossRef
2.
Zurück zum Zitat Barett AP (1986) Oral complications in bone marrow transplantation. Aust N Z J Med 16:239–40CrossRef Barett AP (1986) Oral complications in bone marrow transplantation. Aust N Z J Med 16:239–40CrossRef
3.
Zurück zum Zitat Blijlevens NMA, Donelly JP, De Pauw BE (2000) Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for heamatological malignancy: an overview. Bone Marrow Transplant 25:1269–1278PubMedCrossRef Blijlevens NMA, Donelly JP, De Pauw BE (2000) Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for heamatological malignancy: an overview. Bone Marrow Transplant 25:1269–1278PubMedCrossRef
4.
Zurück zum Zitat Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK (1992) Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69:2469–2477PubMedCrossRef Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK (1992) Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69:2469–2477PubMedCrossRef
5.
Zurück zum Zitat Woo SB, Sonis ST, Monopoli MM, Sonis AL (1993) A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72:1612–1617PubMedCrossRef Woo SB, Sonis ST, Monopoli MM, Sonis AL (1993) A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72:1612–1617PubMedCrossRef
6.
Zurück zum Zitat Vagliano L, Feraut C, Gobetto G et al (2011) Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT—results of a multicenter study. Bone Marrow Transplant 46:727–732PubMedCrossRef Vagliano L, Feraut C, Gobetto G et al (2011) Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT—results of a multicenter study. Bone Marrow Transplant 46:727–732PubMedCrossRef
7.
Zurück zum Zitat Mattsson T, Heimdahl A, Dahllöf G, Lönnqvist B, Nilsson B, Ringdén O (1991) Variables predicting oral mucosal lesions in allogeneic bone marrow recipients. Head Neck 13:224–229PubMedCrossRef Mattsson T, Heimdahl A, Dahllöf G, Lönnqvist B, Nilsson B, Ringdén O (1991) Variables predicting oral mucosal lesions in allogeneic bone marrow recipients. Head Neck 13:224–229PubMedCrossRef
8.
Zurück zum Zitat Dahllöf G, Heimdahl A, Bolme P, Lönnqvist B, Ringdén O (1988) Oral condition in children treated with bone marrow transplantation. Bone Marrow Transplant 3:43–51PubMed Dahllöf G, Heimdahl A, Bolme P, Lönnqvist B, Ringdén O (1988) Oral condition in children treated with bone marrow transplantation. Bone Marrow Transplant 3:43–51PubMed
9.
Zurück zum Zitat Sonis ST (2009) Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45:1015–1020PubMedCrossRef Sonis ST (2009) Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45:1015–1020PubMedCrossRef
10.
Zurück zum Zitat Donelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, DePauw BE (1992) A scheme for daily monitoring of oral mucositis in allogenic BMT recipients. Bone Marrow Transplant 9:409–413 Donelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, DePauw BE (1992) A scheme for daily monitoring of oral mucositis in allogenic BMT recipients. Bone Marrow Transplant 9:409–413
11.
Zurück zum Zitat Tabbara I, Zimmerman K, Morgan C, Naleh Z (2002) Allogenic hematopoietic stem cell transplantation. Complications and results. Arch Intern Med 162:1558–1566PubMedCrossRef Tabbara I, Zimmerman K, Morgan C, Naleh Z (2002) Allogenic hematopoietic stem cell transplantation. Complications and results. Arch Intern Med 162:1558–1566PubMedCrossRef
12.
Zurück zum Zitat Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S (2007) Oral mucositis and outcomes of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Support Care Cancer 15:491–496PubMedCrossRef Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S (2007) Oral mucositis and outcomes of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Support Care Cancer 15:491–496PubMedCrossRef
13.
Zurück zum Zitat Ringdén O, Le Blanc K (2005) Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 113:813–30PubMedCrossRef Ringdén O, Le Blanc K (2005) Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 113:813–30PubMedCrossRef
14.
Zurück zum Zitat Ringdén O, Labopin M, Ehninger G et al (2009) Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplant in patients with acute myeloid leukemia. J Clin Oncol 27:4570–4577PubMedCrossRef Ringdén O, Labopin M, Ehninger G et al (2009) Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplant in patients with acute myeloid leukemia. J Clin Oncol 27:4570–4577PubMedCrossRef
15.
Zurück zum Zitat Giralt S, Estey E, Albitar M et al (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531–4536PubMed Giralt S, Estey E, Albitar M et al (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531–4536PubMed
16.
Zurück zum Zitat McSweeney PA, Niederwieser D, Shizuru JA et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390–3400PubMedCrossRef McSweeney PA, Niederwieser D, Shizuru JA et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390–3400PubMedCrossRef
17.
Zurück zum Zitat World Health Organization (1979) WHO handbook for reporting results for cancer treatment, vol 48. World Health Organization, Geneva, p 1 World Health Organization (1979) WHO handbook for reporting results for cancer treatment, vol 48. World Health Organization, Geneva, p 1
18.
Zurück zum Zitat Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem cell transplantation. J Clin Oncol 19:2201–2205PubMed Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem cell transplantation. J Clin Oncol 19:2201–2205PubMed
19.
Zurück zum Zitat Svahn BM, Remberger M, Myrbäck KE et al (2002) Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 100:4317–4324PubMedCrossRef Svahn BM, Remberger M, Myrbäck KE et al (2002) Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 100:4317–4324PubMedCrossRef
20.
Zurück zum Zitat Schaffer M, Aldener-Cannavá A, Remberger M, Ringdén O, Olerup O (2003) Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 62:243–250PubMedCrossRef Schaffer M, Aldener-Cannavá A, Remberger M, Ringdén O, Olerup O (2003) Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 62:243–250PubMedCrossRef
21.
Zurück zum Zitat Storb R, Deeg HJ, Fisher L et al (1988) Cyclosporine vs methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 71:293–298PubMed Storb R, Deeg HJ, Fisher L et al (1988) Cyclosporine vs methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 71:293–298PubMed
22.
Zurück zum Zitat Ringdén O, Remberger M, Persson U et al (1995) Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 15:619–1625PubMed Ringdén O, Remberger M, Persson U et al (1995) Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 15:619–1625PubMed
23.
Zurück zum Zitat Ringdén O, Uzunel M, Rasmusson I et al (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390–1397PubMedCrossRef Ringdén O, Uzunel M, Rasmusson I et al (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390–1397PubMedCrossRef
24.
Zurück zum Zitat Lundgren G, Wilczek H, Lönnqvist B, Lindholm A, Wahren B, Ringdén O (1985) Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis 47:137–144 Lundgren G, Wilczek H, Lönnqvist B, Lindholm A, Wahren B, Ringdén O (1985) Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis 47:137–144
25.
Zurück zum Zitat National Cancer Institute (2003) Common terminology criteria for adverse events (CTCAE). Version 3.0 ed. Cancer Therapy Evaluation Program, Bethesda National Cancer Institute (2003) Common terminology criteria for adverse events (CTCAE). Version 3.0 ed. Cancer Therapy Evaluation Program, Bethesda
26.
Zurück zum Zitat Sonis S, Edwards L, Lucey C (1999) The biological basis for the attenuation of mucositis: the example of interleukin-11. Leukemia 13:831–834PubMedCrossRef Sonis S, Edwards L, Lucey C (1999) The biological basis for the attenuation of mucositis: the example of interleukin-11. Leukemia 13:831–834PubMedCrossRef
27.
Zurück zum Zitat Lockhart PB, Sonis ST (1981) Alterations in the oral mucosa caused by chemotherapeutic agents: a histologic study. J Dermatol Surg Oncol 7:1019–1025PubMedCrossRef Lockhart PB, Sonis ST (1981) Alterations in the oral mucosa caused by chemotherapeutic agents: a histologic study. J Dermatol Surg Oncol 7:1019–1025PubMedCrossRef
28.
Zurück zum Zitat Dorr W, Spekl K, Martin M (2002) Radiation-induced oral mucositis in mice: strain differences. Cell Prolif 35:60–67PubMedCrossRef Dorr W, Spekl K, Martin M (2002) Radiation-induced oral mucositis in mice: strain differences. Cell Prolif 35:60–67PubMedCrossRef
29.
Zurück zum Zitat Ulrich CM, Yasui Y, Storb R et al (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98:231–234PubMedCrossRef Ulrich CM, Yasui Y, Storb R et al (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98:231–234PubMedCrossRef
30.
Zurück zum Zitat Hassan MG, Oberg AN, Bekassy J et al (1991) Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28:130–134PubMedCrossRef Hassan MG, Oberg AN, Bekassy J et al (1991) Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28:130–134PubMedCrossRef
32.
Zurück zum Zitat Keefe D, Schubert M, Elting L et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef Keefe D, Schubert M, Elting L et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef
33.
Zurück zum Zitat Bhatt V, Vendrell N, Nau K, Crumb D, Roy V (2010) Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract 16:195–204PubMedCrossRef Bhatt V, Vendrell N, Nau K, Crumb D, Roy V (2010) Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract 16:195–204PubMedCrossRef
34.
Zurück zum Zitat Katrancı N, Ovayolu N, Ovayolu O, Sevinc A (2012) Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy—a randomized controlled trial. Eur J Oncol Nurs 16:339–344PubMedCrossRef Katrancı N, Ovayolu N, Ovayolu O, Sevinc A (2012) Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy—a randomized controlled trial. Eur J Oncol Nurs 16:339–344PubMedCrossRef
35.
Zurück zum Zitat Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025PubMedCrossRef Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025PubMedCrossRef
36.
Zurück zum Zitat Barasch A, Peterson DE (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39:91–100PubMedCrossRef Barasch A, Peterson DE (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39:91–100PubMedCrossRef
37.
Zurück zum Zitat Rapoport AP, Miller Watelet LF, Linder T et al (1999) Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 17:2446–2453PubMed Rapoport AP, Miller Watelet LF, Linder T et al (1999) Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 17:2446–2453PubMed
38.
Zurück zum Zitat Dreizen S (1990) Description and incidence of oral complications. NCI Monogr 9:11–15PubMed Dreizen S (1990) Description and incidence of oral complications. NCI Monogr 9:11–15PubMed
Metadaten
Titel
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients
verfasst von
Karin Garming Legert
Mats Remberger
Olle Ringdén
Anders Heimdahl
Göran Dahllöf
Publikationsdatum
01.08.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2190-7

Weitere Artikel der Ausgabe 8/2014

Supportive Care in Cancer 8/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.